Le Lézard
Classified in: Health, Science and technology
Subject: RCL

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination


CHARLOTTESVILLE, Va., Sept. 29, 2023 /PRNewswire/ -- Biomic Sciences is voluntarily recalling all lots of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray products to the consumer level. FDA testing found the product to contain microbial contamination identified as Microbacterium sp., Fictibacillus sp., Bacillus sp., (primarily B. malikii), and Paenibacillus sp (these microorganisms are generally non-pathogenic).  

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

The product is used as a nasal rinse and is packaged in individual boxes of one or two nasal spray dispensers (see the product pictures below).  All lots of the of the following products are covered by this recall:

Product Name

Sales Period

ION* Sinus Support 

September 2021 through September 20, 2023

ION* Biome Sinus

September 2019 through September 2021

Restore Sinus Spray 

June 2017 through September 2019

The affected lots were distributed to wholesale and retail outlets, as well as sold directly to consumers online. 

Biomic Sciences is notifying its distributors and customers by electronic communications and is arranging for the disposition of all recalled products.  Consumers and other parties that have the recalled product should stop using the product and either discard it or take a photo of the lot number on the bottom of the bottle before discarding it and provide that to Biomic Sciences to arrange a refund (contact information provided below). 

Parties with questions about this recall can contact ION* Sinus Recall Team at 1-844-715-0113 Monday ? Friday from 9:00 am to 5:00 pm Eastern time or [email protected]. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

SOURCE Biomic Sciences


These press releases may also interest you

at 06:18
With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...

at 05:50
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:35
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...

at 05:02
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...

at 05:00
WellSync, an API-driven virtual care service provider, today announced its partnership with The Vitamin Shoppe to launch Whole Health Rx, a cutting-edge telehealth service providing access to GLP-1 medications for weight management. WellSync provides...

at 04:00
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...



News published on and distributed by: